[Skip to Content]
[Skip to Content Landing]
Article
June 1979

Treatment of Osteogenic Sarcoma of the Mandible

Author Affiliations

From the Department of Otolaryngology (Dr deFries), the Division of Medical Oncology, Department of Medicine (Dr Perlin), and the Division of Radiotherapy, Department of Radiology (Dr Leibel), National Naval Medical Center, Bethesda, Md, and the Division of Otolaryngology (Dr deFries) and the Department of Medicine (Dr Perlin), Uniformed Services University of the Health Sciences, Bethesda, Md. Dr deFries is now with The Johns Hopkins University School of Medicine, Baltimore.

Arch Otolaryngol. 1979;105(6):358-359. doi:10.1001/archotol.1979.00790180056013
Abstract

• Osteogenic sarcoma of the mandible is a rare tumor, comprising less than 0.5% of all head and neck tumors, and, even in large institutions, the experience in management of such tumors is limited. Current therapy for osteogenic sarcoma of the long bones is based on a more extensive experience in large centers and includes a major role for chemotherapy. We report two cases of osteogenic sarcoma of the mandible that were treated by combined chemotherapy, radiation therapy, and surgery. The expected diseasefree survival of patients with this disease, treated by surgery alone, would have been less than 50% in the first year. The survival of these two consecutive patients for more than one year, free of disease, is significant and encourages further use of this type of treatment.

(Arch Otolaryngol 105:358-359, 1979)

×